Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Selley

Showing results (121-130 of 149) with videos related to

Pageof 15
Sort By:
ACS Chemical Neuroscience|November 30, 2022
Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine AnaloguesMengchu Li, David L Stevens, Michelle Arriaga, et al.
ACS Chemical Neuroscience|June 9, 2016
6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR LigandDwight A Williams, Yi Zheng, Bethany G David, et al.
Molecular Pharmacology|September 27, 2007
CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1aJason L Niehaus, Yunguang Liu, Kathleen T Wallis, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 19, 2016
Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro AssaysT W Grim, A J Morales, M M Gonek, et al.
ACS Pharmacology & Translational Science|December 19, 2024
Discovery of 6α-Thiazolylcarboxamidonaltrexamine Derivative (NTZ) as a Potent and Central Nervous System Penetrant Opioid Receptor Modulator with Drug-like Properties for Potential Treatment of Opioid Use DisorderBoshi Huang, Hongguang Ma, Piyusha P Pagare, et al.
Bioorganic Chemistry|February 25, 2021
Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[(4'-pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptorsBoshi Huang, Rama Gunta, Huiqun Wang, et al.
Bioorganic & Medicinal Chemistry|October 11, 2016
Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerizationChristopher K Arnatt, Bethany A Falls, Yunyun Yuan, et al.
Cell Reports|July 28, 2015
Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid ActionAndreu Viader, Jacqueline L Blankman, Peng Zhong, et al.
Pharmacology Research & Perspectives|June 29, 2023
Role of efficacy as a determinant of locomotor activation by mu-opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR-selective phenylmorphans with high-to-low MOR efficacyEdna J Santos, Nima Nassehi, Eric W Bow, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 EntryHongguang Ma, Huiqun Wang, Mengchu Li, et al.
Pageof 15

Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
ACS Chemical Neuroscience|November 30, 2022
Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine AnaloguesMengchu Li, David L Stevens, Michelle Arriaga, et al.
ACS Chemical Neuroscience|June 9, 2016
6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR LigandDwight A Williams, Yi Zheng, Bethany G David, et al.
Molecular Pharmacology|September 27, 2007
CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1aJason L Niehaus, Yunguang Liu, Kathleen T Wallis, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 19, 2016
Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro AssaysT W Grim, A J Morales, M M Gonek, et al.
ACS Pharmacology & Translational Science|December 19, 2024
Discovery of 6α-Thiazolylcarboxamidonaltrexamine Derivative (NTZ) as a Potent and Central Nervous System Penetrant Opioid Receptor Modulator with Drug-like Properties for Potential Treatment of Opioid Use DisorderBoshi Huang, Hongguang Ma, Piyusha P Pagare, et al.
Bioorganic Chemistry|February 25, 2021
Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[(4'-pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptorsBoshi Huang, Rama Gunta, Huiqun Wang, et al.
Bioorganic & Medicinal Chemistry|October 11, 2016
Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerizationChristopher K Arnatt, Bethany A Falls, Yunyun Yuan, et al.
Cell Reports|July 28, 2015
Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid ActionAndreu Viader, Jacqueline L Blankman, Peng Zhong, et al.
Pharmacology Research & Perspectives|June 29, 2023
Role of efficacy as a determinant of locomotor activation by mu-opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR-selective phenylmorphans with high-to-low MOR efficacyEdna J Santos, Nima Nassehi, Eric W Bow, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 EntryHongguang Ma, Huiqun Wang, Mengchu Li, et al.
Pageof 15